

**Uni-Bio Science Announces Changes to the Board of Directors
Strengthens the Group in Expansion of Business in China**

* * * *

***Mr. Kingsley Leung Promoted to Chairman and Executive Director and
Mr. Chen Da Wei Appointed as Vice Chairman and Executive Director***

(Hong Kong, 13 January 2017) – **Uni-Bio Science Group Limited** (“Uni-Bio Science” or the “Group”; HKEx code: 690) has today announced that Mr. Kingsley Leung, who currently is an Executive Director of the Board, is promoted to Chairman and Executive Director, while Mr. Chen Da Wei has been appointed as Vice Chairman and Executive Director of the Group, effective 13 January, 2017. Meanwhile, the Board has also announced that the current Chairman and Executive Director, Mr. Tong Kit Shing, is to retire effective today after a distinguished career of more than 11 years with the company.

Mr. Tong Kit Shing, Chairman and Executive Director of Uni-Bio Science said, *“It has been a privilege and a pleasure to serve Uni-Bio Science, its employees, shareholders, business partners and customers. It has been immensely gratifying to watch this company’s steady growth into an industry-leading expert in diabetes management. Now is the right time to hand the reins over to those who can take the company to the next level, and I have the utmost confidence that Mr. Leung and Mr. Chen together with our excellent executive team will continue to thoroughly and comprehensively address the pressing needs for the provision of high-quality Chinese healthcare solutions and deliver on both its long-term and short-term performance goals and promise.”*

Mr. Kingsley Leung, Executive Director of Uni-Bio Science said, *“On behalf of the Board of Uni-Bio Science, I would like to welcome Mr. Chen to the Board as Vice Chairman and Executive Director. Mr. Chen has extensive experience with and insight into China’s enterprises and capital market, which will certainly lead the Group in building a broad network in the capital market and accelerate the expansion of business in China. At the same time, the Group would like to thank Mr. Tong for his contributions to Uni-Bio Science, Mr. Tong has been one of Uni-Bio Science’s guiding lights over the years, providing inspirational leadership for the team and setting an example through his own hard work, integrity and determination. Looking ahead, the Group will leverage its broad and well-established marketing teams, dedicated R&D team focused on the discovery of innovative new therapies and our clinical pipeline rich with upcoming projects to seize emerging opportunities in China’s growing healthcare market which complement our R&D capabilities and comprehensive diabetes treatment portfolio. We will endeavour to be the leading partner for global healthcare companies and execute our comprehensive strategy in satisfying currently unmet treatment needs.”*

Mr. Kingsley Leung joined Uni-Bio Science as an Executive Director in 2014. Prior to that, Mr. Leung has extensive experience in investment banking and business development in biotechnology industry. He is a Chartered Financial Analyst and a member of The Hong Kong Society of Financial Analysts. Mr. Leung graduated with honours with a Bachelor's degree in Biochemistry from Imperial College London and obtained a Master's degree in Pharmacology from the University of Oxford. He is currently admitted to Tsinghua-INSEAD Executive MBA Programme.

Mr. Chen Da Wei, the new Vice Chairman and Executive Director of the Group, has more than 20 years of experience in enterprise management, capital market and merger and acquisition. He has set up and invested in companies, and has accumulated abundant operational experience in both domestic and foreign capital markets. Over the years, Mr. Chen had taken the roles as Chairman, Chief Executive Office, Executive Director and Vice Chairman of China Everbright Water Limited (formerly known as HanKore Environment Tech Group Limited), which is listed on the Main Board of the Singapore Exchange Limited and the sole water business platform of China Everbright Group Ltd. Currently, he is the Executive Partner of a Chinese equity investment fund and the Chairman of a Singapore capital management company. He has earned an Executive Master's degree in Business Administration (major in China-America Finance) from Peking University, and the Master's degree in Business Administration from the National University of Singapore. Mr. Chen presently holds around a 6.15% equity interest in the Group.

This strengthened team is ideally suited to accelerate Uni-Bio Science's progress to become the leading provider of innovative treatments and solutions for diabetes management in China whilst fostering the values and principles of Uni-Bio Science. The Group is poised to advance to the next level through dynamic teamwork, and continuous dedication to the pursuit of quality, as well as innovative deployment of resources in discovering new therapies.

– End –

About Uni-Bio Science Group Limited (SEHK: 0690)

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center located in Dongguan, PRC is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with CFDA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments addressing the therapeutic areas of diabetes, ophthalmology and dermatology.

Media Enquiries:

Strategic Financial Relations Limited

Veron Ng Phone: +852 2864 4831
Phoebe Li Phone: +852 2864 4862
 Fax: +852 2527 1196

Email: veron.ng@sprg.com.hk
Email: phoebe.li@sprg.com.hk

WeChat ID: Unibio-IR

心 創 造 新 醫 藥
LEADING GENUINE INNOVATION

